News | March 03, 2022
Merck KGaA reports higher profits on strong volumes across its businesses
Company expects strong organic growth in sales, EBITDA in 2022
Company expects strong organic growth in sales, EBITDA in 2022
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
The bulk drug plants that have already been commissioned include CDA, para amino phenol, atorvastatin, sulfadiazine, oxcarbazepine, levofloxacin, carbidopa and levodopa
This new mandate builds upon and strengthens Azelis and Roquette’s global strategic partnership which spans multiple regions and industries.
Haleon will have a portfolio of category-leading brands including Sensodyne, Voltaren, Panadol and Centrum
He will continue to lead business in LATAM and Asia regions in this new role
The researchers are of the view that the new drug designing strategy demonstrated by them could also be adopted to treat retroviral infections.
The companies plan to use the proceeds to retire debt and expand operations
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
Occupancy is expected to be in the range of 60-62% while Average Revenue Per Occupied Bed (ARPOB) is expected to expand by least 6% in FY2022
Subscribe To Our Newsletter & Stay Updated
